1. Celltrion acquired Imclone Systems from Eli Lilly for $330 million, indicating strategic realignment. 2. The sale could impact Eli Lilly's financials and focus on core operations.
The divestiture of Imclone may cause short-term financial decline, similar to LLY's previous sell-offs which led to temporary price drops as investor confidence wavered.
The acquisition reflects LLY's strategic shifts and financial health, but may raise concerns among investors, potentially impacting stock performance.
The immediate financial effects from the acquisition announcement could influence LLY's stock price quickly, similar to past divestitures impacting quarterly performance.